close
Jump to content

Lymphoma

From Wikipedia, the free encyclopedia
(Redirected from Lymphomas)

Lymphoma
Illustration depicting lymphoma developing in the lymphatic system
SpecialtyHematology and oncology
SymptomsEnlarged lymph nodes, fever, sweats, unintended weight loss, itching, feeling tired[1][2]
Risk factorsEpstein–Barr virus, autoimmune diseases, HIV/AIDS, tobacco smoking[2][3]
Diagnostic methodLymph node biopsy[1][2]
TreatmentChemotherapy, radiation therapy, proton therapy, targeted therapy, surgery[1][2]
PrognosisAverage five year survival 85% (USA)[4]
Frequency4.9 million (2015)[5]
Deaths204,700 (2015)[6]

Lymphoma is a group of blood and lymph tumors that develop from lymphocytes (a type of white blood cell).[7] The name typically refers to just the cancerous versions rather than all such tumors.[7] Signs and symptoms may include enlarged lymph nodes, fever, drenching sweats, unintended weight loss, itching, and constantly feeling tired.[1][2] The enlarged lymph nodes are usually painless.[1] The sweats are most common at night.[1][2]

The two main categories of lymphomas are the non-Hodgkin lymphoma (NHL) (90% of cases)[8][9] and Hodgkin lymphoma (HL) (10%).[8] Lymphomas, leukemias and myelomas are a part of the broader group of tumors of the hematopoietic and lymphoid tissues.[10]

Risk factors for Hodgkin lymphoma include infection with Epstein–Barr virus and a history of the disease in the family.[1] Risk factors for common types of non-Hodgkin lymphomas include autoimmune diseases, HIV/AIDS, infection with human T-lymphotropic virus, immunosuppressant medications, and some pesticides.[2][11] Eating large amounts of red meat and tobacco smoking may also increase the risk.[3][12][13] Diagnosis, if enlarged lymph nodes are present, is usually by lymph node biopsy.[1][2] Blood, urine, and bone marrow testing may also be useful in the diagnosis.[2] Medical imaging may then be done to determine if and where the cancer has spread.[1][2] Lymphoma most often spreads to the lungs, liver, and brain.[1][2]

Treatment may involve one or more of the following: chemotherapy, radiation therapy, proton therapy, targeted therapy, and surgery.[1][2] In some non-Hodgkin lymphomas, an increased amount of protein produced by the lymphoma cells causes the blood to become so thick that plasmapheresis is performed to remove the protein.[2] Watchful waiting may be appropriate for certain types.[2] The outcome depends on the subtype, with some being curable and treatment prolonging survival in most.[8] The five-year survival rate in the United States for all Hodgkin lymphoma subtypes is 89%,[4] while that for non-Hodgkin lymphomas is 74%.[14] Worldwide, lymphomas developed in 566,000 people in 2012 and caused 305,000 deaths.[15] They make up 3–4% of all cancers, making them as a group the seventh-most-common form.[15][16] In children, they are the third-most-common cancer.[17] They occur more often in the developed world than in the developing world.[15]

Signs and symptoms

[edit]
The lymph nodes where lymphoma most commonly develops

Lymphoma commonly presents with painless, persistent lymphadenopathy[18] (swelling of the lymph nodes) and can vary from rapidly enlarging lymph nodes in aggressive lymphomas to fluctuating lymphadenopathy in slow-growing subtypes.[19] Constitutional symptoms may also occur[20] but are nonspecific and overlap with many common diseases.[21]

B symptoms are a trio of systemic symptoms consisting of fever, night sweats, and unintended weight loss commonly associated with both Hodgkin and non-Hodgkin lymphomas.[18] Patients with more advanced lymphoma are more likely to be affected by these symptoms.[19]

Extranodal involvement, or the presence of lymphoma outside the lymph nodes, can cause a variety of symptoms related to the affected organ.[22] These symptoms are common with subtypes of aggressive non-Hodgkin lymphoma, and rarer with indolent lymphomas.[23]

Mediastinal lymphadenopathy, and less commonly pulmonary lymphoma, may cause cough, dyspnea, chest pain, or superior vena cava syndrome, due to compression of adjacent thoracic structures.[24][25]

Bone marrow involvement can cause anemia, thrombocytopenia, and fatigue.[26][27] This is most common in low-grade, non-Hodgkin lymphomas, especially in follicular, mantle cell, and small B-cell lymphomas (40-90% of cases depending on subtype).[28][29][30]

Chronic pain, fullness, early satiety, and gastrointestinal bleeding are symptoms associated with gastrointestinal lymphoma.[23] The gastrointestinal tract is the most common location for extranodal involvement with non-Hodgkin lymphomas, accounting for 30-40% of extranodal lymphomas in general.[31] In Hodgkin lymphomas, gastrointestinal involvement is rare, accounting for less than 1% of gastric lymphomas.[32]

Although uncommon, involvement with the central nervous system can cause symptoms including confusion, double vision, headaches, nausea, and hearing loss.[33] It is rare in Hodgkin lymphomas, with only 0.2% to 0.5% of patients experiencing it,[34][35] but occurs more often in non-Hodgkin lymphoma, from 2.8% in indolent forms to 24.4% in high-grade lymphoblastic and Burkitt lymphoma.[36]

Paraneoplastic syndromes are rare in lymphoma.[37] Paraneoplastic cerebellar degeneration is most strongly associated with Hodgkin lymphomas, while polymyositis and dermatomyositis are associated with both Hodgkin and non-Hodgkin lymphomas.[37][19]

Diagnosis

[edit]
An initial evaluation of a suspected lymphoma is to make a "touch prep" wherein a glass slide is lightly pressed against excised lymphoid tissue, and subsequently stained (usually H&E stain) for evaluation under light microscopy.

Lymphoma is definitively diagnosed by a lymph-node biopsy, meaning a partial or total excision of a lymph node examined under the microscope.[38] This examination reveals histopathological features that may indicate lymphoma. After lymphoma is diagnosed, a variety of tests may be carried out to look for specific features characteristic of different types of lymphoma. These include:[39]

Classification

[edit]
Lymph node with mantle cell lymphoma (low-power view, H&E)

According to the World Health Organization (WHO), lymphoma classification should reflect in which lymphocyte population the neoplasm arises.[40] Thus, neoplasms that arise from precursor lymphoid cells are distinguished from those that arise from mature lymphoid cells.[40] Most mature lymphoid neoplasms comprise the non-Hodgkin lymphomas.[40] Historically, mature histiocytic and dendritic cell (HDC) neoplasms have been considered[by whom?] mature lymphoid neoplasms, since these often involve lymphoid tissue.[40]

Lymphoma can also spread to the central nervous system, often around the brain in the meninges, known as lymphomatous meningitis (LM).[41]

Hodgkin lymphoma

[edit]

Hodgkin lymphoma accounts for about 10% of lymphomas.[8] It differs from other forms of lymphomas in its prognosis and several pathological characteristics. A division into Hodgkin and non-Hodgkin lymphomas is used in several of the older classification systems. A Hodgkin lymphoma is marked by the presence of a type of cell called the Reed–Sternberg cell.[42][43]

Non-Hodgkin lymphomas

[edit]

Non-Hodgkin lymphomas, which are defined as all lymphomas except Hodgkin lymphoma, are more common than Hodgkin lymphoma. A wide variety of lymphomas are in this class, and the causes, the types of cells involved, and the prognoses vary by type. The number of cases annually of non-Hodgkin lymphoma increases with age. It is further divided into several subtypes.[44]

Epstein–Barr virus-associated lymphoproliferative diseases

[edit]
Follicular lymphoma replacing a lymph node

Epstein–Barr virus-associated lymphoproliferative diseases are a group of benign, premalignant, and malignant diseases of lymphoid cells (i.e., B cells, T cells, NK cells, and histiocytic-dendritic cells) in which one or more of these cell types is infected with the Epstein–Barr virus (EBV). The virus may be responsible for the development and/or progression of these diseases. In addition to EBV-positive Hodgkin lymphomas, the World Health Organization (2016) includes the following lymphomas, when associated with EBV infection, in this group of diseases: Burkitt lymphoma; large B cell lymphoma, not otherwise specified; diffuse large B cell lymphoma associated with chronic inflammation; fibrin-associated diffuse large B cell lymphoma; primary effusion lymphoma; plasmablastic lymphoma; extranodal NK/T cell lymphoma, nasal type; peripheral T cell lymphoma, not otherwise specified; angioimmunoblastic T-cell lymphoma; follicular T cell lymphoma; and systemic T cell lymphoma of childhood.[45]

WHO classification

[edit]

The WHO classification, published in 2001 and updated in 2008, 2017, and 2022,[46] is based upon the foundations laid within the "revised European–American lymphoma classification" (REAL). This system groups lymphomas by cell type (i.e., the normal cell type that most resembles the tumor) and defines phenotypic, molecular, or cytogenetic characteristics. The five groups are shown in the table. Hodgkin lymphoma is considered separately within the WHO and preceding classifications, although it is recognized as being a tumor, albeit markedly abnormal, of lymphocytes of mature B cell lineage.[47]

Of the many forms of lymphoma, some are categorized as indolent (e.g., small lymphocytic lymphoma), compatible with a long life even without treatment. Other forms are aggressive (e.g., Burkitt's lymphoma), causing rapid deterioration and death. However, most of the aggressive lymphomas respond well to treatment and are curable. The prognosis, therefore, depends on the correct diagnosis and classification of the disease, which is established after examination of a biopsy by a pathologist (usually a hematopathologist).[48]

Lymphoma subtypes (WHO 2008)
Mature B cell neoplasms
DNA-microarray analysis of Burkitt's lymphoma and diffuse large B-cell lymphoma (DLBCL) showing differences in gene expression patterns. Colors indicate levels of expression; green indicates genes that are underexpressed in lymphoma cells (as compared to normal cells), whereas red indicates genes that are overexpressed in lymphoma cells.
3–4% of lymphomas in adults
Small resting lymphocytes mixed with variable numbers of large activated cells, lymph nodes diffusely effaced
CD5, surface immunoglobulin
5-year survival rate 50%.[49]
Occurs in older adults, usually involves lymph nodes, bone marrow, and spleen; most patients have peripheral blood involvement, indolent
About 5% of lymphomas in adults
Variable cell size and differentiation, 40% show plasma cell differentiation, homing of B cells to epithelium creates lymphoepithelial lesions.
CD5, CD10, surface Ig
Frequently occurs outside lymph nodes, very indolent, may be cured by local excision
About 40% of lymphomas in adults
Small "cleaved" [cleft] cells (centrocytes) mixed with large activated cells (centroblasts), usually nodular ("follicular") growth pattern
CD10, surface Ig
About 72–77%[50]
Occurs in older adults, usually involves lymph nodes, bone marrow, and spleen, associated with t(14;18) translocation overexpressing Bcl-2, indolent
About 3–4% of lymphomas in adults
Lymphocytes of small to intermediate size growing in a diffuse pattern
CD5
About 50[51] to 70%[51]
Occurs mainly in adult males, usually involves lymph nodes, bone marrow, spleen, and GI tract, associated with t(11;14) translocation overexpressing cyclin D1, moderately aggressive
About 40–50% of lymphomas in adults
Variable, most resemble B cells of large germinal centers, diffuse growth pattern
Variable expression of CD10 and surface Ig
Five-year survival rate 60%[52]
Occurs in all ages, but most commonly in older adults, may occur outside lymph nodes, aggressive
< 1% of lymphomas in the United States
Round lymphoid cells of intermediate size with several nucleoli, starry-sky appearance by diffuse spread with interspersed apoptosis
CD10, surface Ig
Five-year survival rate 50%[53]
Endemic in Africa, sporadic elsewhere, more common in immunocompromised and children, often visceral involvement, highly aggressive
Mature T cell and natural killer (NK) cell neoplasms
Most common cutaneous lymphoid malignancy
Usually small lymphoid cells with convoluted nuclei that often infiltrate the epidermis, creating Pautrier microabscesseses
CD4
5-year survival 75%[54]
Localized or more generalized skin symptoms, generally indolent, in a more aggressive variant, Sézary's disease, skin erythema and peripheral blood involvement
Most common T cell lymphoma
Variable, usually a mix of small to large lymphoid cells with irregular nuclear contours
CD3
Probably consists of several rare tumor types, often disseminated and generally aggressive
Precursor lymphoid neoplasms
15% of childhood acute lymphoblastic leukemia and 90% of lymphoblastic lymphoma.[55]: 635 
Lymphoblasts with irregular nuclear contours, condensed chromatin, small nucleoli, and scant cytoplasm without granules
TdT, CD2, CD7
It often presents as a mediastinal mass because of involvement of the thymus. It is highly associated with NOTCH1 mutations, and is most common in adolescent males.
Hodgkin lymphoma
Most common type of Hodgkin lymphoma
Reed–Sternberg cell variants and inflammation, usually broad sclerotic bands that consist of collagen
CD15, CD30
Most common in young adults, often arises in the mediastinum or cervical lymph nodes
    • Mixed cellularity Hodgkin lymphoma
Second-most common form of Hodgkin lymphoma
Many classic Reed–Sternberg cells and inflammation
CD15, CD30
Most common in men, more likely to be diagnosed at advanced stages than the nodular sclerosis form Epstein–Barr virus involved in 70% of cases
Immunodeficiency-associated lymphoproliferative disorders
  • Associated with a primary immune disorder
  • Associated with the human immunodeficiency virus (HIV)
  • Post-transplant
  • Associated with methotrexate therapy
  • Primary central nervous system lymphoma occurs most often in immunocompromised patients, in particular those with AIDS, but it can occur in the immunocompetent, as well. It has a poor prognosis, particularly in those with AIDS. Treatment can consist of corticosteroids, radiotherapy, and chemotherapy, often with methotrexate.

Previous classifications

[edit]

Several previous classifications have been used, including Rappaport, Lennert/Kiel, BNLI, Working Formulation, and REAL. [56]

The Working Formulation of 1982 was a classification of non-Hodgkin lymphoma. It excluded the Hodgkin lymphomas and divided the remaining lymphomas into four grades (low, intermediate, high, and miscellaneous) related to prognosis, with some further subdivisions based on the size and shape of affected cells. This purely histological classification included no information about cell surface markers or genetics and made no distinction between T-cell lymphomas and B-cell lymphomas. It was widely accepted at the time of its publication, but by 2004, it was obsolete.[57]

In 1994, the Revised European-American Lymphoma (REAL) classification applied immunophenotypic and genetic features to identify distinct clinicopathologic entities among all the lymphomas except Hodgkin lymphoma.[27] For coding purposes, the ICD-O (codes 9590–9999)[58] and ICD-10 (codes C81-C96)[59] are available.

Staging

[edit]
Diagram showing common sites where lymphoma spreads

After a diagnosis and before treatment, cancer is staged. This refers to determining if the cancer has spread, and if so, whether locally or to distant sites. Staging is reported as a grade from I (confined) to IV (spread). The stage of a lymphoma helps predict a patient's prognosis and is used to help select the appropriate therapy.[60]

The Ann Arbor staging system is routinely used for staging of both HL and NHL. In this staging system, stage I represents localized disease contained within a lymph node group, II represents the presence of lymphoma in two or more lymph node groups, III represents spread of the lymphoma to lymph node groups on both sides of the diaphragm, and IV indicates spread to tissue outside the lymphatic system. Different suffixes imply the involvement of different organs, for example, S for the spleen and H for the liver. Extra-lymphatic involvement is expressed with the letter E. In addition, the presence of B symptoms (one or more of the following: unintentional loss of 10% body weight in the last 6 months, night sweats, or persistent fever of 38 °C or more) or their absence is expressed with B or A, respectively.[61]

CT scan or PET scan imaging modalities are used to stage cancer. PET scanning is advised for fluorodeoxyglucose-avid lymphomas, such as Hodgkin lymphoma, as a staging tool that can even replace bone marrow biopsy. For other lymphomas, CT scanning is recommended for staging.[60]

Age and poor performance status are other established poor prognostic factors.[62] This means that people who are elderly or too sick to take care of themselves are more likely to be killed by lymphoma than others.

Differential diagnosis

[edit]

Certain lymphomas (extranodal NK/T-cell lymphoma, nasal type and type II enteropathy-associated T-cell lymphoma) can be mimicked by two benign diseases that involve the excessive proliferation of nonmalignant NK cells in the GI tract, natural killer cell enteropathy, a disease wherein NK cell infiltrative lesions occur in the intestine, colon, stomach, or esophagus, and lymphomatoid gastropathy, a disease wherein these cells' infiltrative lesions are limited to the stomach. These diseases do not progress to cancer, may regress spontaneously, and do not respond to or require chemotherapy or other lymphoma treatments.[63]

Treatment

[edit]

The treatment of lymphoma varies greatly, depending on disease subtype, Ann Arbor staging, anatomical distribution, and patient factors like age, symptoms, and performance status.[64] For aggressive and advanced-stage lymphomas, treatment is often administered with the intent to cure[65], while treatment for slow-growing lymphomas involve more watchful waiting and focus on symptom alleviation.[66]

Treatment may involve a combination of modalities, including chemotherapy, radiation therapy, immunotherapy, targeted therapy, hematopoietic stem-cell transplants, or simply watchful waiting.[67][68][69] Advancements in diagnostics have allowed more individual treatment based on lymphoma subtype and patient circumstances.[70]

Hodgkin lymphoma

[edit]

The management of Hodgkin lymphoma differs from non-Hodgkin subtypes due to its predictable pattern of spreading through the lymphatic system and the presence of Reed-Sternberg cells.[71][72] The disease is responsive to treatment, with 5-year survival rates exceeding 80% across all stages.[73][74][75]

Early-stage disease

[edit]

Early-stage (I-II) classical Hodgkin lymphoma is generally treated with chemotherapy, the standard regimen being ABVD, paired with involved-site radiotherapy[69][76], a radiotherapy technique where only areas directly affected by disease are targeted instead of entire anatomical regions.[77] Increasingly, PET imaging has been used to adapt regimens, based on the patient's response to treatment, allowing for escalation to BEACOPP or other treatments in unfavourable progression.[78] Classifying patients based on initial risk has also been used to make modifications in treatment.[79]

Late-stage disease

[edit]

Treatments for advanced-stage (III-IV) Hodgkin lymphoma have gone through significant development since the late 2010s, with the standard of care expanding from ABVD to include therapies incorporating brentuximab vedotin, an antibody-drug conjugate that targets CD30 proteins expressed on Reed-Sternberg cells[80], combined with doxorubicin, vinblastine, and dacarbazine (BV-AVD)[69][81] More recently, nivolumab, an immune checkpoint inhibitor that promotes T-cell anti-tumor activity by targeting the PD-1 receptor[82][83], has been used in first-line treatment with the same chemotherapy regimen (N-AVD).[84]

Refractory or relapsed disease

[edit]

Patients with refractory or relapsed Hodgkin lymphoma are often treated with salvage chemotherapy followed by hematopoietic stem-cell transplantation, with around 50% of relapsed patients being cured.[85][86] In patients where relapse occurs after stem-cell transplantation, brentuximab vedotin and PD-1 inhibitors are viable options for treatment, and have been shown to reduce relapse risk.[87][88]

Non-Hodgkin lymphoma

[edit]

Non-Hodgkin lymphoma encompasses over 80 distinct diseases,[89][90] with treatments varying according to subtype and clinical behaviour, broadly divided into indolent and aggressive lymphomas.[91] Outcomes of treatment are varied, with 5-year overall survival ranging from 60-90% depending on patient risk and subtype of lymphoma.[92][93]

Aggressive disease

[edit]

Aggressive B-cell lymphomas, like diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma, are typically treated with combination chemotherapy, with the goal of complete cure.[94] The most common regimen is rituximab, an immunotherapy that targets the CD20 protein expressed on B-cells, combined with CHOP chemotherapy (R-CHOP)[95], which has been the first-line standard for over 20 years.[96]

Polatuzumab vedotin, an antibody-drug conjugate that targets the CD79b protein on B-cells to deliver monomethyl auristatin E, has been recently introduced as an alternative to R-CHOP in the Pola-R-CHP regimen, where it replaces the mitotic inhibitor vincristine (Oncovin).[97][98]

Indolent disease

[edit]

Localised indolent lymphomas, especially stage I follicular lymphoma, may be treated with involved-site radiotherapy, with the intent to cure.[99] 5-year overall survival for both early-stage follicular and marginal zone lymphoma treated with radiotherapy have been reported to exceed 85%.[100] Rituximab, both with and without chemotherapy, is also an accepted alternative for patients where radiotherapy is unavailable as a treatment.[101]

Contrary to localised disease, advanced-stage indolent lymphomas are often treated with watchful waiting when patients are asymptomatic and have a low tumour burden, as early treatment has not been shown to improve overall survival.[102][103][104] Treatment is indicated following development of symptoms or high tumor burden.[105][106]

When initiated, standard treatment includes rituximab with bendamustine, an alkylating chemotherapeutic agent with DNA-damaging properties,[107] however, combinations of rituximab and other chemotherapies are used as well.[99]

In other lymphomas, like chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL), Bruton's tyrosine kinase (BTK) inhibitors, a targeted therapy that prevents B-cells from growing by blocking B-cell receptor signalling, are widely used as standard chemotherapy-free treatments.[108]

Relapsed or refractory disease

[edit]

With the advent of targeted therapy and immunotherapy-based treatments, treatment of relapsed and refractory non-Hodgkin lymphoma has increasingly incorporated modalities beyond salvage chemotherapy and stem-cell transplantation.[109][110]

Chimeric antigen receptor-modified (CAR) T-cell therapy has become part of the standard of care in refractory B-cell lymphomas[110], where, through the genetic modification of patient T-cells, CD19 proteins on B cells are targeted to release cytotoxins in tumor cells.[111][112] Remission rates have improved with the introduction of CAR T-cell therapy, with 31% of patients remaining progression-free at 5 years[113] and a complete remission rate of 59%[114] in comparison to 40% complete remission and 25% progression-free survival with prior treatments.[115]

Bispecific antibodies, an immunotherapy that binds to two proteins simultaneously (CD20 on lymphoma cells, CD3 on T-cells) to direct T cells to target B cells, have also demonstrated efficacy in relapsed diffuse large B-cell lymphoma and follicular lymphoma and provided alternative treatment options for patients ineligible for CAR-T therapy.[116] Response rates range from 25-40% in diffuse large B-cell lymphoma, and 60-75% in follicular lymphoma.[117]

For refractory or relapsed mantle cell lymphoma, BCL-2 inhibitors, like venetoclax, and BTK inhibitors block signalling pathways, inducing apoptosis with a 21% complete response rate.[118]

Palliative care

[edit]

Palliative care, a specialized medical care focused on the symptoms, pain, and stress of a serious illness, is recommended by multiple national cancer treatment guidelines as an accompaniment to curative treatments for people with lymphoma.[119][120] It is used to address both the direct symptoms of lymphoma and many unwanted side effects that arise from treatments.[121][122] Palliative care can be especially helpful for children who develop lymphoma, helping both children and their families deal with the physical and emotional symptoms of the disease.[121][123][124][125] For these reasons, palliative care is especially important for people requiring bone marrow transplants.[126][127]

Supportive treatment

[edit]

Adding physical exercises to the standard treatment for adult patients with haematological malignancies like lymphomas may result in little to no difference in mortality, quality of life, and physical functioning. These exercises may result in a slight reduction in depression. Furthermore, aerobic physical exercises probably reduce fatigue. The evidence is very uncertain about the effect on anxiety and serious adverse events.[128]

Prognosis

[edit]
Five-year relative survival by stage at diagnosis[129]
Stage at diagnosis Five-year relative
survival (%)		 Percentage
of cases (%)
Localized (confined to primary site) 82.3 26
Regional (spread to regional lymph nodes) 78.3 19
Distant (cancer has metastasized) 62.7 47
Unknown (unstaged) 68.6 8

Epidemiology

[edit]
Deaths from lymphomas and multiple myeloma per million persons in 2012:
  0–13
  14–18
  19–22
  23–28
  29–34
  35–42
  43–57
  58–88
  89–121
  122–184

Between 1990 and 2021, Lymphoma was the most common form of hematological malignancy, or "blood cancer", in the developed world.[130]

Taken together, lymphomas represent 5.3% of all cancers (excluding simple basal cell and squamous cell skin cancers) in the United States and 55.6% of all blood cancers.[131]

According to the U.S. National Institutes of Health, lymphomas account for about 5%, and Hodgkin lymphoma in particular accounts for less than 1% of all cases of cancer in the United States.[132]

Because the whole lymphatic system is part of the body's immune system, people with a weakened immune system, such as from HIV infection or certain drugs or medications, also have a higher number of cases of lymphoma.[133]

History

[edit]
Thomas Hodgkin

Thomas Hodgkin published the first description of lymphoma in 1832, specifically of the form named after him.[134] Since then, many other forms of lymphoma have been described.[weasel words]

The term "lymphoma" is from Latin lympha ("water") and from Greek -oma ("morbid growth, tumor").[135]

Research

[edit]

The two types of lymphoma research are clinical or translational research and basic research. Clinical/translational research focuses on studying the disease in a defined and generally immediately applicable way, such as testing a new drug in people. Studies may focus on effective means of treatment, better ways of treating the disease, improving the quality of life for people, or appropriate care in remission or after cures. Hundreds of clinical trials are being planned or conducted at any given time.[136]

Basic science research studies the disease process at a distance, such as seeing whether a suspected carcinogen can cause healthy cells to turn into lymphoma cells in the laboratory or how the DNA changes inside lymphoma cells as the disease progresses. The results from basic research studies are generally less immediately useful to people with the disease,[137] but can improve scientists' understanding of lymphoma and form the foundation for future, more effective treatments.

Other animals

[edit]

References

[edit]
  1. 1 2 3 4 5 6 7 8 9 10 11 "General Information About Adult Hodgkin Lymphoma". National Cancer Institute. 2014-04-23. Archived from the original on 5 July 2014. Retrieved 20 June 2014.
  2. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 "General Information About Adult Non-Hodgkin Lymphoma". National Cancer Institute. 2014-04-25. Archived from the original on 5 July 2014. Retrieved 20 June 2014.
  3. 1 2 Kamper-Jørgensen M, Rostgaard K, Glaser SL, Zahm SH, Cozen W, Smedby KE, et al. (September 2013). "Cigarette smoking and risk of Hodgkin lymphoma and its subtypes: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph)". Annals of Oncology. 24 (9): 2245–2255. doi:10.1093/annonc/mdt218. PMC 3755332. PMID 23788758.
  4. 1 2 "Hodgkin Lymphoma—SEER Stat Fact Sheets". Seer.cancer.gov. Retrieved 6 January 2026.
  5. ↑ Allen C, Arora M, Barber RM, Bhutta ZA, Brown A, Carter A, et al. (GBD 2015 Disease and Injury Incidence and Prevalence Collaborators) (October 2016). "Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1545–1602. doi:10.1016/S0140-6736(16)31678-6. PMC 5055577. PMID 27733282.
  6. ↑ Wang H, et al. (October 2016). "Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015". Lancet. 388 (10053): 1459–1544. doi:10.1016/s0140-6736(16)31012-1. PMC 5388903. PMID 27733281.
  7. 1 2 Taylor EJ (2000). Dorland's Illustrated medical dictionary (29th ed.). Philadelphia: Saunders. p. 1038. ISBN 0-7216-6254-4.
  8. 1 2 3 4 "The Lymphoma Guide Information for Patients and Caregivers" (PDF). Leukemia and Lymphoma Society. 2013. Archived (PDF) from the original on 14 July 2014. Retrieved 20 June 2014.
  9. ↑ "Lymphoma". NCI. 2011-02-02. Archived from the original on 5 July 2014. Retrieved 13 June 2014.
  10. ↑ Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. (July 2009). "The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes". Blood. 114 (5): 937–951. doi:10.1182/blood-2009-03-209262. PMID 19357394. S2CID 3101472.
  11. ↑ Hu L, Luo D, Zhou T, Tao Y, Feng J, Mei S (December 2017). "The association between non-Hodgkin lymphoma and organophosphate pesticides exposure: A meta-analysis". Environmental Pollution. 231 (Pt 1): 319–328. Bibcode:2017EPoll.231..319H. doi:10.1016/j.envpol.2017.08.028. PMID 28810201.
  12. ↑ Yang L, Dong J, Jiang S, Shi W, Xu X, Huang H, et al. (November 2015). "Red and Processed Meat Consumption Increases Risk for Non-Hodgkin Lymphoma: A PRISMA-Compliant Meta-Analysis of Observational Studies". Medicine. 94 (45) e1729. doi:10.1097/MD.0000000000001729. PMC 4912242. PMID 26559248.
  13. ↑ Solimini AG, Lombardi AM, Palazzo C, De Giusti M (May 2016). "Meat intake and non-Hodgkin lymphoma: a meta-analysis of observational studies". Cancer Causes & Control. 27 (5): 595–606. doi:10.1007/s10552-016-0745-2. hdl:11573/865541. PMID 27076059. S2CID 17430078.
  14. ↑ "SEER Stat Fact Sheets: Non-Hodgkin Lymphoma". NCI. Retrieved 6 January 2026.
  15. 1 2 3 World Cancer Report 2014. World Health Organization. 2014. pp. Chapter 5.13. ISBN 978-92-832-0429-9.
  16. ↑ Marcus R (2013). Lymphoma: pathology, diagnosis and treatment (Second ed.). Cambridge University Press. p. 1. ISBN 978-1-107-01059-8. Archived from the original on 2015-09-06.
  17. ↑ Tepper JE, Kastan MB, Doroshow JH, Armitage JO, Niederhuber JE (2014). "Childhood lymphoma". Abeloff's clinical oncology (Fifth ed.). Elsevier. p. Chapter 97. ISBN 978-1-4557-2865-7.
  18. 1 2 "About Lymphoma". Lymphoma Research Foundation. Archived from the original on 2 December 2012. Retrieved 22 December 2012.
  19. 1 2 3 Lewis WD, Lilly S, Jones KL (2020-01-01). "Lymphoma: Diagnosis and Treatment". American Family Physician. 101 (1): 34–41. ISSN 1532-0650. PMID 31894937.
  20. ↑ "Lymphoma Symptoms, Hodgkin & Non-Hodgkin". moffitt. Retrieved 2026-06-27.
  21. ↑ "Diagnosing Lymphoma". Lymphoma Research Foundation. Retrieved 2026-06-27.
  22. ↑ Ansell SM (2015-08-01). "Non-Hodgkin Lymphoma: Diagnosis and Treatment". Mayo Clinic Proceedings. 90 (8): 1152–1163. doi:10.1016/j.mayocp.2015.04.025. ISSN 0025-6196. PMID 26250731.
  23. 1 2 Freedman AS, Nadler LM (2003), "Differential diagnosis and sites of disease at presentation", Holland-Frei Cancer Medicine. 6th edition, BC Decker, retrieved 2026-06-28
  24. ↑ Higdon ML, Atkinson CJ, Lawrence KV (2018-06-01). "Oncologic Emergencies: Recognition and Initial Management". American Family Physician. 97 (11): 741–748. ISSN 1532-0650. PMID 30215936.
  25. ↑ Vadde R, Pastores SM (December 2016). "Management of Acute Respiratory Failure in Patients With Hematological Malignancy". Journal of Intensive Care Medicine. 31 (10): 627–641. doi:10.1177/0885066615601046. ISSN 1525-1489. PMC 5582028. PMID 26283185.
  26. ↑ Paquin AR, Oyogoa E, McMurry HS, Kartika T, West M, Shatzel JJ (January 2023). "The diagnosis and management of suspected lymphoma in general practice". European Journal of Haematology. 110 (1): 3–13. doi:10.1111/ejh.13863. ISSN 1600-0609. PMC 10042228. PMID 36093749.
  27. 1 2 Non-Hodgkin Lymphoma at eMedicine
  28. ↑ Kato D, Yoshioka S, Yabushita T, Shimomura Y, Ono Y, Hiramoto N, Yonetani N, Matsushita A, Hashimoto H, Ishikawa T (2016-12-02). "The Clinical Impact of Minimal Bone Marrow Involvement on the Outcome of Patients with Follicular Lymphoma". Blood. 128 (22): 2966. doi:10.1182/blood.V128.22.2966.2966. ISSN 0006-4971.
  29. ↑ Sachanas S, Pangalis GA, Fink AM, Bahlo J, Fischer K, Levidou G, Kyrtsonis MC, Bartzi V, Vassilakopoulos TP, Kalpadakis C, Koulieris E, Moschogiannis M, Yiakoumis X, Tsirkinidis P, Angelopoulou MK (2019-05-01). "Small Lymphocytic Lymphoma: Analysis of Two Cohorts Including Patients in Clinical Trials of the German Chronic Lymphocytic Leukemia Study Group (GCLLSG) or in "Real-Life" Outside of Clinical Trials". Anticancer Research. 39 (5): 2591–2598. doi:10.21873/anticanres.13382. ISSN 0250-7005. PMID 31092457.
  30. ↑ Park Y, Park BB, Jeong JY, Kim WY, Jang S, Shin BK, Lee DS, Han JH, Park CJ, Suh C, Kim I, Chi HS (November 2016). "Assessment of bone marrow involvement in patients with lymphoma: report on a consensus meeting of the Korean Society of Hematology Lymphoma Working Party". The Korean Journal of Internal Medicine. 31 (6): 1030–1041. doi:10.3904/kjim.2015.006. ISSN 2005-6648. PMC 5094919. PMID 27809449.
  31. ↑ Shirwaikar Thomas A, Schwartz M, Quigley E (2019). "Gastrointestinal lymphoma: the new mimic". BMJ Open Gastroenterology. 6 (1) e000320. doi:10.1136/bmjgast-2019-000320. ISSN 2054-4774. PMC 6782046. PMID 31645987.
  32. ↑ "aplm". aplm.kglmeridian.com. Retrieved 2026-06-28.
  33. ↑ "Lymphoma - Symptoms and causes". Mayo Clinic. Archived from the original on 2026-06-23. Retrieved 2026-06-28.
  34. ↑ Gerstner ER, Abrey LE, Schiff D, Ferreri AJ, Lister A, Montoto S, Tsang R, Thiel E, Graus F, Behringer D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris NL (2008-09-01). "CNS Hodgkin lymphoma". Blood. 112 (5): 1658–1661. doi:10.1182/blood-2008-04-151563. ISSN 1528-0020. PMC 3710443. PMID 18591379.
  35. ↑ Ahmed S, Irfan B, Raza M, Haider G (2021-10-29). "Atypical involvement of central nervous system in classic Hodgkin lymphoma: a case report". Journal of Medical Case Reports. 15 (1): 532. doi:10.1186/s13256-021-03118-4. ISSN 1752-1947. PMC 8555165. PMID 34711281.
  36. ↑ Hollender A, Kvaloy S, Nome O, Skovlund E, Lote K, Holte H (July 2002). "Central nervous system involvement following diagnosis ofnon-Hodgkin's lymphoma: a risk model". Annals of Oncology. 13 (7): 1099–1107. doi:10.1093/annonc/mdf175. PMID 12176790.
  37. 1 2 Graus F, Ariño H, Dalmau J (2014-05-22). "Paraneoplastic neurological syndromes in Hodgkin and non-Hodgkin lymphomas". Blood. 123 (21): 3230–3238. doi:10.1182/blood-2014-03-537506. ISSN 1528-0020. PMC 4046430. PMID 24705493.
  38. ↑ "Types of Biopsies". Lymphoma Research Foundation. Retrieved 2026-07-01.
  39. ↑ "Understanding Your Lymphoma Diagnosis: Making Sense of Over 100 Different Types". Lymphoma Research Foundation. Retrieved 2026-07-01.
  40. 1 2 3 4 Manli Jiang, N. Nora Bennani, and Andrew L. Feldman. Lymphoma classification update: T-cell lymphomas, Hodgkin lymphoma, and histiocytic/dendritic cell neoplasms. Expert Rev Hematol. 2017 Mar; 10(3): 239–249. Author Manuscript.
  41. ↑ Canova F, Marino D, Trentin C, Soldà C, Ghiotto C, Aversa SM (August 2011). "Intrathecal chemotherapy in lymphomatous meningitis". Critical Reviews in Oncology/Hematology. 79 (2): 127–134. doi:10.1016/j.critrevonc.2010.07.005. PMID 20696592.
  42. ↑ National Cancer Institute, "Hodgkin Lymphoma", "Lymphoma—Patient Version". Archived from the original on 2013-08-02. Retrieved 2013-08-05., accessed on 2013-08-05
  43. ↑ National Cancer Institute. "What You Need To Know About Hodgkin Lymphoma". U.S. Dept of Health and Human Services, (online at "Archived copy" (PDF). Archived from the original (PDF) on 2014-01-24. Retrieved 2013-08-05.{{cite web}}: CS1 maint: archived copy as title (link)), pg 4.
  44. ↑ Britto TI, Fattah SA, Rahman MA, Chowdhury MA, Britto TI, Fattah SA, Rahman MA, Chowdhury MA (2023-09-25). "A Systematic Review on Childhood Non-Hodgkin Lymphoma: An Overlooked Phenomenon in the Health and Research Sector of Bangladesh". Cureus. 15 (9) e45937. doi:10.7759/cureus.45937. ISSN 2168-8184. PMC 10601349. PMID 37900448.
  45. ↑ Rezk SA, Zhao X, Weiss LM (September 2018). "Epstein-Barr virus (EBV)-associated lymphoid proliferations, a 2018 update". Human Pathology. 79: 18–41. doi:10.1016/j.humpath.2018.05.020. PMID 29885408. S2CID 47010934.
  46. ↑ Naresh KN, Medeiros LJ (December 2023). "Introduction to the Fifth Edition of the World Health Organization Classification of Tumors of Hematopoietic and Lymphoid Tissues". Modern Pathology. 36 (12) 100330. doi:10.1016/j.modpat.2023.100330. PMID 37716508.
  47. ↑ Britto TI, Fattah SA, Rahman M, Chowdhury M (2023-09-25). "A Systematic Review on Childhood Non-Hodgkin Lymphoma: An Overlooked Phenomenon in the Health and Research Sector of Bangladesh". Cureus. 15 (9) e45937. doi:10.7759/cureus.45937. PMC 10601349. PMID 37900448.
  48. ↑ Wagman LD. (2008). "Principles of Surgical Oncology". In Pazdur R, Wagman LD, Camphausen KA, Hoskins WJ (eds.). Cancer Management: A Multidisciplinary Approach (11th ed.). CMPMedica. ISBN 978-1-891483-62-2. Archived from the original on 2013-10-04.
  49. ↑ "Chronic Leukemias". The Merck Manual of Geriatrics. Archived from the original on 2010-07-04.
  50. ↑ Lymphoma, Follicular at eMedicine
  51. 1 2
    50% for limited stage: Leitch HA, Gascoyne RD, Chhanabhai M, Voss NJ, Klasa R, Connors JM (October 2003). "Limited-stage mantle-cell lymphoma". Annals of Oncology. 14 (10): 1555–1561. doi:10.1093/annonc/mdg414. PMID 14504058.
    70% for advanced stage: Herrmann A, Hoster E, Zwingers T, Brittinger G, Engelhard M, Meusers P, et al. (February 2009). "Improvement of overall survival in advanced stage mantle cell lymphoma". Journal of Clinical Oncology. 27 (4): 511–518. doi:10.1200/JCO.2008.16.8435. PMID 19075279. S2CID 32350562.
  52. ↑ Turgeon ML (2005). Clinical Hematology: Theory and Procedures. Vol. 936 (4 ed.). Lippincott Williams & Wilkins. pp. 285–6. ISBN 978-0-7817-5007-3. Archived from the original on 2015-09-06.
  53. ↑ Diviné M, Casassus P, Koscielny S, Bosq J, Sebban C, Le Maignan C, et al. (December 2005). "Burkitt lymphoma in adults: a prospective study of 72 patients treated with an adapted pediatric LMB protocol". Annals of Oncology. 16 (12): 1928–1935. doi:10.1093/annonc/mdi403. PMID 16284057.
  54. ↑ Kirova YM, Piedbois Y, Haddad E, Levy E, Calitchi E, Marinello G, Le Bourgeois JP (May 1999). "Radiotherapy in the management of mycosis fungoides: indications, results, prognosis. Twenty years experience". Radiotherapy and Oncology. 51 (2): 147–151. doi:10.1016/S0167-8140(99)00050-X. PMID 10435806.
  55. ↑ Jaffe ES, Harris NL, Vardiman JW, Campo E, Arber D (2011). Hematopathology (1st ed.). Elsevier Saunders. ISBN 978-0-7216-0040-6.
  56. ↑ Piccaluga PP (2024-12-11), "Introductory Chapter: Lymphoma Classification – A Long Route to Precision Medicine", Advances in Hematological Malignancies, IntechOpen, ISBN 978-1-83768-299-7, retrieved 2026-07-01{{citation}}: CS1 maint: work parameter with ISBN (link)
  57. ↑ Clarke CA, Glaser SL, Dorfman RF, Bracci PM, Eberle E, Holly EA (January 2004). "Expert review of non-Hodgkin's lymphomas in a population-based cancer registry: reliability of diagnosis and subtype classifications". Cancer Epidemiology, Biomarkers & Prevention. 13 (1): 138–143. doi:10.1158/1055-9965.EPI-03-0250. PMID 14744745.
  58. ↑ Percy C, Holten Vv, Muir CS (1990). International classification of diseases for oncology. World Health Organization. hdl:10665/39441. ISBN 978-92-4-154414-6.[page needed]
  59. ↑ "2022 ICD-10-CM Codes C81-C96: Malignant neoplasms of lymphoid, hematopoietic and related tissue". www.icd10data.com. Archived from the original on 2022-01-17. Retrieved 2022-02-02.
  60. 1 2 Cheson BD, Fisher RI, Barrington SF, Cavalli F, Schwartz LH, Zucca E, Lister TA (September 2014). "Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification". Journal of Clinical Oncology. 32 (27): 3059–3068. doi:10.1200/JCO.2013.54.8800. PMC 4979083. PMID 25113753.
  61. ↑ Carbone PP, Kaplan HS, Musshoff K, Smithers DW, Tubiana M (November 1971). "Report of the Committee on Hodgkin's Disease Staging Classification". Cancer Research. 31 (11): 1860–1861. PMID 5121694.
  62. ↑ International Non-Hodgkin's Lymphoma Prognostic Factors Project (September 1993). "A predictive model for aggressive non-Hodgkin's lymphoma". The New England Journal of Medicine. 329 (14): 987–994. doi:10.1056/NEJM199309303291402. PMID 8141877.
  63. ↑ Xia D, Morgan EA, Berger D, Pinkus GS, Ferry JA, Zukerberg LR (January 2019). "NK-Cell Enteropathy and Similar Indolent Lymphoproliferative Disorders: A Case Series With Literature Review". American Journal of Clinical Pathology. 151 (1): 75–85. doi:10.1093/ajcp/aqy108. PMID 30212873. S2CID 52272766.
  64. ↑ Sapkota S, Shaikh H (2026), "Non-Hodgkin Lymphoma", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32644754, retrieved 2026-06-29
  65. ↑ Ansell SM, Nowakowski GS (2026-03-10). "Current treatment algorithm: diffuse large B cell lymphoma". Blood Cancer Journal. 16 (1): 32. doi:10.1038/s41408-026-01458-2. ISSN 2044-5385. PMC 13002880. PMID 41803085.
  66. ↑ Jeong SH (2022-04-30). "Treatment of indolent lymphoma". Blood Research. 57 (S1): 120–129. doi:10.5045/br.2022.2022054. ISSN 2287-979X. PMC 9057664. PMID 35483936.
  67. ↑ Ngu H, Takiar R, Phillips T, Okosun J, Sehn LH (April 2022). "Revising the Treatment Pathways in Lymphoma: New Standards of Care-How Do We Choose?". American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting. 42 (42): 629–642. doi:10.1200/EDBK_349307. ISSN 1548-8756. PMID 35594501.
  68. ↑ Bröckelmann PJ, Eichenauer DA, Jakob T, Follmann M, Engert A, Skoetz N (2018-08-06). "Hodgkin Lymphoma in Adults". Deutsches Arzteblatt International. 115 (31–32): 535–540. doi:10.3238/arztebl.2018.0535. ISSN 1866-0452. PMC 6131364. PMID 30149835.
  69. 1 2 3 "Hodgkin Lymphoma Treatment & Management: Approach Considerations, Goals of Therapy and Response Assessment, Radiation Therapy". 2026-03-31. {{cite journal}}: Cite journal requires |journal= (help)
  70. ↑ "Hodgkin Lymphoma Treatment & Management: Approach Considerations, Goals of Therapy and Response Assessment, Radiation Therapy". 2026-03-31. {{cite journal}}: Cite journal requires |journal= (help)
  71. ↑ Yadav G, Singh A, Jain M, Kushwaha R, Verma SP (2022). "Reed Sternberg-Like Cells in Non-Hodgkin Lymphoma: A Diagnostic Challenge". Discoveries (Craiova, Romania). 10 (3): e155. doi:10.15190/d.2022.14. ISSN 2359-7232. PMC 9754675. PMID 36540090.
  72. ↑ Constine LS, Yahalom J, Ng AK, Hodgson DC, Wirth A, Milgrom SA, Mikhaeel NG, Eich HT, Illidge T, Ricardi U, Dieckmann K, Moskowitz CH, Advani R, Mauch PM, Specht L (2018-04-01). "The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group". International Journal of Radiation Oncology, Biology, Physics. 100 (5): 1100–1118. doi:10.1016/j.ijrobp.2018.01.011. hdl:2318/1682827. ISSN 1879-355X. PMID 29722655.
  73. ↑ Johnson PW (2023). "Are we reaching the maximum cure rate for Hodgkin lymphoma?". Hematological Oncology. 41 (S1): 57–61. doi:10.1002/hon.3140. ISSN 1099-1069. PMID 37294968.
  74. ↑ "Hodgkin Lymphoma - Cancer Stat Facts". SEER. Retrieved 2026-07-01.
  75. ↑ Bhurani D, Nair R, Rajappa S, Rao SA, Sridharan N, Boya RR, Raman GS, Menon H, Seshachalam A, Nimmagadda R (2021). "Real-World Outcomes of Hodgkin Lymphoma: A Multi-Centric Registry From India". Frontiers in Oncology. 11 799948. doi:10.3389/fonc.2021.799948. ISSN 2234-943X. PMC 8881143. PMID 35223455.
  76. ↑ Mohty R, Dulery R, Bazarbachi AH, Savani M, Hamed RA, Bazarbachi A, Mohty M (2021-07-09). "Latest advances in the management of classical Hodgkin lymphoma: the era of novel therapies". Blood Cancer Journal. 11 (7): 126. doi:10.1038/s41408-021-00518-z. ISSN 2044-5385. PMC 8270913. PMID 34244478.
  77. ↑ Theodor Eich, Hans, Benedikt Pepper, Niklas, Michael O (December 2023). "Evolution of Radiation Fields from Involved Field to Involved Site�A Summary of the Current Guidelines by the International Lymphoma Radiation Oncology Group". Lymphatics. 1 (3): 262–272. doi:10.3390/lymphatics1030017. ISSN 2813-3307. {{cite journal}}: replacement character in |title= at position 67 (help)CS1 maint: multiple names: authors list (link)
  78. ↑ Ansell SM (2024). "Hodgkin lymphoma: 2025 update on diagnosis, risk-stratification, and management". American Journal of Hematology. 99 (12): 2367–2378. doi:10.1002/ajh.27470. ISSN 1096-8652. PMID 39239794.
  79. ↑ Keller FG, Kahl B, Friedberg JW (November 2023). "Current directions in the treatment of classical Hodgkin lymphoma". eJHaem. 4 (4): 908–911. doi:10.1002/jha2.784. ISSN 2688-6146. PMC 10660392. PMID 38024613.
  80. ↑ van de Donk NW, Dhimolea E (2012). "Brentuximab vedotin". mAbs. 4 (4): 458–465. doi:10.4161/mabs.20230. ISSN 1942-0870. PMC 3499340. PMID 22684302.
  81. ↑ Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Alekseev S, Illés Á, Picardi M, Lech-Maranda E, Oki Y, Feldman T, Smolewski P, Savage KJ (2018-01-25). "Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma". The New England Journal of Medicine. 378 (4): 331–344. doi:10.1056/NEJMoa1708984. ISSN 1533-4406. PMC 5819601. PMID 29224502.
  82. ↑ Guo L, Zhang H, Chen B (2017). "Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor". Journal of Cancer. 8 (3): 410–416. doi:10.7150/jca.17144. ISSN 1837-9664. PMC 5332892. PMID 28261342.
  83. ↑ Rendon A, Rayi A (2026), "Nivolumab", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 33620870, retrieved 2026-07-02
  84. ↑ PDQ Adult Treatment Editorial Board (2002), "Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version", PDQ Cancer Information Summaries, Bethesda (MD): National Cancer Institute (US), PMID 26389473, retrieved 2026-07-02
  85. ↑ Shanbhag S, Ambinder RF (March 2018). "Hodgkin lymphoma: A review and update on recent progress". CA: A Cancer Journal for Clinicians. 68 (2): 116–132. doi:10.3322/caac.21438. ISSN 1542-4863. PMC 5842098. PMID 29194581.
  86. ↑ Varma G, Diefenbach C (2024-08-01). "The role of autologous stem-cell transplantation in classical Hodgkin lymphoma in the modern era". Seminars in Hematology. 61 (4): 253–262. doi:10.1053/j.seminhematol.2024.06.003. ISSN 0037-1963. PMID 39039012.
  87. ↑ Sureda A, Pavlovsky A, Haidar D, Kristo F, Stache V, Zomas A (June 2025). "Real-world outcomes of brentuximab vedotin as consolidation therapy after autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma: A systematic review and meta-analysis". Bone Marrow Transplantation. 60 (6): 820–831. doi:10.1038/s41409-025-02557-7. ISSN 1476-5365. PMC 12151861. PMID 40200006.
  88. ↑ Carlo-Stella C, Ricci F, Dalto S, Mazza R, Malagola M, Patriarca F, Viviani S, Russo D, Giordano L, Castagna L, Corradini P, Santoro A (March 2015). "Brentuximab vedotin in patients with Hodgkin lymphoma and a failed allogeneic stem cell transplantation: results from a named patient program at four Italian centers". The Oncologist. 20 (3): 323–328. doi:10.1634/theoncologist.2014-0420. ISSN 1549-490X. PMC 4350807. PMID 25669663.
  89. ↑ Li W (2022), Li W (ed.), "The 5th Edition of the World Health Organization Classification of Hematolymphoid Tumors", Leukemia, Brisbane (AU): Exon Publications, ISBN 978-0-6453320-7-0, PMID 36395314, retrieved 2026-07-03{{citation}}: CS1 maint: work parameter with ISBN (link)
  90. ↑ "Non-Hodgkin Lymphoma". Lymphoma Research Foundation. 2026-07-02. Retrieved 2026-07-03.
  91. ↑ Ansell SM, Armitage J (August 2005). "Non-Hodgkin lymphoma: diagnosis and treatment". Mayo Clinic Proceedings. 80 (8): 1087–1097. doi:10.4065/80.8.1087. ISSN 0025-6196. PMID 16092591.
  92. ↑ Garg M, Takyar J, Dhawan A, Saggu G, Agrawal N, Hall A, Raut M, Ryland KE (2022-11-15). "Diffuse Large B-Cell Lymphoma (DLBCL): A Structured Literature Review of the Epidemiology, Treatment Guidelines, and Real-World Treatment Patterns". Blood. 140 (Supplement 1): 12106–12107. doi:10.1182/blood-2022-169045. ISSN 0006-4971.
  93. ↑ "Non-Hodgkin Lymphoma - Cancer Stat Facts". SEER. Retrieved 2026-07-03.
  94. ↑ Ansell SM, Nowakowski GS (2026-03-10). "Current treatment algorithm: diffuse large B cell lymphoma". Blood Cancer Journal. 16 (1): 32. doi:10.1038/s41408-026-01458-2. ISSN 2044-5385. PMC 13002880. PMID 41803085.
  95. ↑ Sapkota S, Shaikh H (2026), "Non-Hodgkin Lymphoma", StatPearls, Treasure Island (FL): StatPearls Publishing, PMID 32644754, retrieved 2026-07-03
  96. ↑ Ansell SM, Nowakowski GS (2026-03-10). "Current treatment algorithm: diffuse large B cell lymphoma". Blood Cancer Journal. 16 (1): 32. doi:10.1038/s41408-026-01458-2. ISSN 2044-5385. PMC 13002880. PMID 41803085.
  97. ↑ "Clinical Review", Polatuzumab Vedotin (Polivy): CADTH Reimbursement Review: Therapeutic area: Large B-cell lymphoma [Internet], Canadian Agency for Drugs and Technologies in Health, February 2024, retrieved 2026-07-03
  98. ↑ Tilly H, Morschhauser F, Sehn LH, Friedberg JW, Trněný M, Sharman JP, Herbaux C, Burke JM, Matasar M, Rai S, Izutsu K, Mehta-Shah N, Oberic L, Chauchet A, Jurczak W (2022-01-26). "Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma". New England Journal of Medicine. 386 (4): 351–363. doi:10.1056/NEJMoa2115304. ISSN 0028-4793. PMC 11702892. PMID 34904799.
  99. 1 2 PDQ Adult Treatment Editorial Board (2002), "Indolent B-Cell Non-Hodgkin Lymphoma Treatment (PDQ®): Health Professional Version", PDQ Cancer Information Summaries, Bethesda (MD): National Cancer Institute (US), PMID 37437080, retrieved 2026-07-04
  100. ↑ Hadi I, Schummer A, Dreyling M, Eze C, Bodensohn R, Roengvoraphoj O, Belka C, Li M (2021-11-19). "Effectiveness and tolerability of radiotherapy for patients with indolent non-Hodgkin's lymphoma: a monocenter analysis". Scientific Reports. 11 (1): 22586. Bibcode:2021NatSR..1122586H. doi:10.1038/s41598-021-01851-w. ISSN 2045-2322. PMC 8604980. PMID 34799601.
  101. ↑ Cartron G, Bachy E, Tilly H, Daguindau N, Pica GM, Bijou F, Mounier C, Clavert A, Damaj GL, Slama B, Casasnovas O, Houot R, Bouabdallah K, Sibon D, Fitoussi O (2023-07-01). "Randomized Phase III Trial Evaluating Subcutaneous Rituximab for the First-Line Treatment of Low-Tumor Burden Follicular Lymphoma: Results of a LYSA Study". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 41 (19): 3523–3533. doi:10.1200/JCO.22.02327. ISSN 1527-7755. PMID 37071836.
  102. ↑ Nastoupil LJ, Sinha R, Byrtek M, Ziemiecki R, Zhou X, Taylor M, Friedberg JW, Link BK, Cerhan JR, Dawson K, Flowers CR (March 2016). "Outcomes following watchful waiting for stage II-IV follicular lymphoma patients in the modern era". British Journal of Haematology. 172 (5): 724–734. doi:10.1111/bjh.13895. ISSN 1365-2141. PMID 26729445.
  103. ↑ Solal-Céligny P, Bellei M, Marcheselli L, Pesce EA, Pileri S, McLaughlin P, Luminari S, Pro B, Montoto S, Ferreri AJ, Deconinck E, Milpied N, Gordon LI, Federico M (2012-11-01). "Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database". Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology. 30 (31): 3848–3853. doi:10.1200/JCO.2010.33.4474. ISSN 1527-7755. PMID 23008294.
  104. ↑ Ardeshna KM, Qian W, Smith P, Braganca N, Lowry L, Patrick P, Warden J, Stevens L, Pocock CF, Miall F, Cunningham D, Davies J, Jack A, Stephens R, Walewski J (April 2014). "Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: an open-label randomised phase 3 trial". The Lancet. Oncology. 15 (4): 424–435. doi:10.1016/S1470-2045(14)70027-0. ISSN 1474-5488. PMID 24602760.
  105. ↑ Barraclough A, Agrawal S, Talaulikar D, Chong G, Yoo E, Cheah CY, Franco N, Nguyen B, Mutsando H, Tahir F, Trotman J, Huang J, Keane C, Lincoln M, Cochrane T (2024-10-01). "Impact and utility of follicular lymphoma GELF criteria in routine care: an Australasian Lymphoma Alliance study". Haematologica. 109 (10): 3338–3345. doi:10.3324/haematol.2023.284538. ISSN 1592-8721. PMC 11443368. PMID 38450504.
  106. ↑ Rueda A, Casanova M, Redondo M, Pérez-Ruiz E, Medina-Pérez A (2012-05-31). "Has the time to come leave the "watch-and-wait" strategy in newly diagnosed asymptomatic follicular lymphoma patients?". BMC Cancer. 12 210. doi:10.1186/1471-2407-12-210. ISSN 1471-2407. PMC 3489567. PMID 22650448.
  107. ↑ Cheson BD, Leoni L (August 2011). "Bendamustine: mechanism of action and clinical data". Clinical Advances in Hematology & Oncology: H&O. 9 (8 Suppl 19): 1–11. ISSN 1543-0790. PMID 22362008.
  108. ↑ Small S, Ma S (August 2021). "Frontline Treatment for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Targeted Therapy vs. Chemoimmunotherapy". Current Hematologic Malignancy Reports. 16 (4): 325–335. doi:10.1007/s11899-021-00637-1. ISSN 1558-822X. PMID 34021874.
  109. ↑ Strüßmann T, Marks R, Wäsch R (2024-05-23). "Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Is There Still a Role for Autologous Stem Cell Transplantation in the CAR T-Cell Era?". Cancers. 16 (11): 1987. doi:10.3390/cancers16111987. ISSN 2072-6694. PMC 11171011. PMID 38893108.
  110. 1 2 Denlinger N, Bond D, Jaglowski S (February 2022). "CAR T-cell therapy for B-cell lymphoma". Current Problems in Cancer. 46 (1): 100826. doi:10.1016/j.currproblcancer.2021.100826. ISSN 1535-6345. PMC 9284423. PMID 35012754.{{cite journal}}: CS1 maint: article number as page number (link)
  111. ↑ Althaus J, Nilius-Eliliwi V, Maghnouj A, Döring S, Schroers R, Hudecek M, Hahn SA, Mika T (2023-08-01). "Cytotoxicity of CD19-CAR-NK92 cells is primarily mediated via perforin/granzyme pathway". Cancer Immunology, Immunotherapy. 72 (8): 2573–2583. doi:10.1007/s00262-023-03443-1. ISSN 1432-0851. PMC 10361870. PMID 37052701.
  112. ↑ Kalim M, Jing R, Li X, Jiang Z, Zheng N, Wang Z, Wei G, Lu Y (2024-04-12). "Essentials of CAR-T Therapy and Associated Microbial Challenges in Long Run Immunotherapy". Journal of Cellular Immunology. 6 (1): 25–50. doi:10.33696/immunology.6.189. ISSN 2689-2812. PMC 11172397. PMID 38883270.
  113. ↑ Chong EA, Ruella M, Schuster SJ (2021-02-17). "Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy". New England Journal of Medicine. 384 (7): 673–674. doi:10.1056/NEJMc2030164. ISSN 0028-4793. PMID 33596362.
  114. ↑ "ASCO Publications". American Society of Clinical Oncology. doi:10.1200/JCO.2025.43.16_suppl.e19004. Retrieved 2026-07-05.
  115. ↑ García-Sancho AM, Cabero A, Gutiérrez NC (2023-12-22). "Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma: New Approved Options". Journal of Clinical Medicine. 13 (1): 70. doi:10.3390/jcm13010070. ISSN 2077-0383. PMC 10779497. PMID 38202077.
  116. ↑ Mihaila RG, Todor SB (2025-08-06). "Bispecific Antibodies-A New Hope for Patients with Diffuse Large B-Cell Lymphoma". Journal of Clinical Medicine. 14 (15): 5534. doi:10.3390/jcm14155534. ISSN 2077-0383. PMC 12347617. PMID 40807154.
  117. ↑ Falchi L, Vardhana SA, Salles GA (2023-02-02). "Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities". Blood. 141 (5): 467–480. doi:10.1182/blood.2021011994. ISSN 0006-4971. PMC 9936308. PMID 36322929.
  118. ↑ Tam CS, Anderson MA, Pott C, Agarwal R, Handunnetti S, Hicks RJ, Burbury K, Turner G, Iulio JD, Bressel M, Westerman D, Lade S, Dreyling M, Dawson SJ, Dawson MA (2018-03-29). "Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma". New England Journal of Medicine. 378 (13): 1211–1223. doi:10.1056/NEJMoa1715519. ISSN 0028-4793. PMID 29590547.
  119. ↑ Ferrell B, Connor SR, Cordes A, Dahlin CM, Fine PG, Hutton N, et al. (June 2007). "The national agenda for quality palliative care: the National Consensus Project and the National Quality Forum". Journal of Pain and Symptom Management. 33 (6): 737–744. doi:10.1016/j.jpainsymman.2007.02.024. PMID 17531914.
  120. ↑
  121. 1 2 Higginson IJ, Evans CJ (2010). "What is the evidence that palliative care teams improve outcomes for cancer patients and their families?". Cancer Journal. 16 (5): 423–435. doi:10.1097/PPO.0b013e3181f684e5. PMID 20890138. S2CID 39881122.
  122. ↑ "Palliative Care: It's for Caregivers Too, Says Study". Archived from the original on 2014-06-01. Retrieved 2014-08-21.
  123. ↑ Heath JA, Clarke NE, Donath SM, McCarthy M, Anderson VA, Wolfe J (January 2010). "Symptoms and suffering at the end of life in children with cancer: an Australian perspective". The Medical Journal of Australia. 192 (2): 71–75. doi:10.5694/j.1326-5377.2010.tb03420.x. PMID 20078405. S2CID 8355159.
  124. ↑ Schmidt P, Otto M, Hechler T, Metzing S, Wolfe J, Zernikow B (September 2013). "Did increased availability of pediatric palliative care lead to improved palliative care outcomes in children with cancer?". Journal of Palliative Medicine. 16 (9): 1034–1039. doi:10.1089/jpm.2013.0014. PMID 23901834.
  125. ↑ Tang ST, Chang WC, Chen JS, Wang HM, Shen WC, Li CY, Liao YC (June 2013). "Course and predictors of depressive symptoms among family caregivers of terminally ill cancer patients until their death". Psycho-Oncology. 22 (6): 1312–1318. doi:10.1002/pon.3141. PMID 22836818. S2CID 31552330.
  126. ↑ Chung HM, Lyckholm LJ, Smith TJ (February 2009). "Palliative care in BMT". Bone Marrow Transplantation. 43 (4): 265–273. doi:10.1038/bmt.2008.436. PMID 19151797. S2CID 20112284.
  127. ↑ "Providing Palliative Care to Family Caregivers Throughout the Bone Marrow Transplantation Trajectory". Archived from the original on 2013-08-12. Retrieved 2014-08-21.
  128. ↑ Knips L, Bergenthal N, Streckmann F, Monsef I, Elter T, Skoetz N (January 2019). Cochrane Haematological Malignancies Group (ed.). "Aerobic physical exercise for adult patients with haematological malignancies". The Cochrane Database of Systematic Reviews. 1 (1) CD009075. doi:10.1002/14651858.CD009075.pub3. PMC 6354325. PMID 30702150.
  129. ↑ "SEER Stat Fact Sheets: Lymphoma". Archived from the original on 2013-10-10.
  130. ↑ Zhou L, Shan D, Zhang Y, Li J, Deng R (2025). "Global, regional, and national disease burden of lymphoma and leukemia attributable to high body mass index: from 1990 to 2021". Frontiers in Nutrition. 12 1592443. doi:10.3389/fnut.2025.1592443. ISSN 2296-861X. PMC 12328193. PMID 40777176.
  131. ↑ Horner MJ, Ries LG, Krapcho M, Neyman N. "SEER Cancer Statistics Review, 1975–2006". Surveillance Epidemiology and End Results (SEER). Bethesda, MD: National Cancer Institute. Archived from the original on 26 September 2009. Retrieved 3 November 2009. Table 1.4: Age-Adjusted SEER Incidence and U.S. Death Rates and 5-Year Relative Survival Rates By Primary Cancer Site, Sex and Time Period
  132. ↑ "Hodgkin Lymphoma". American Cancer Society. Archived from the original on 2024-04-22. Retrieved 2024-04-22.
  133. ↑ Tran H, Nourse J, Hall S, Green M, Griffiths L, Gandhi MK (September 2008). "Immunodeficiency-associated lymphomas". Blood Reviews. 22 (5): 261–281. doi:10.1016/j.blre.2008.03.009. PMID 18456377.
  134. ↑ Hellman S, Mauch, P.M. Ed. (1999). "Chapter 1". Hodgkin's Disease. Lippincott Williams & Wilkins. p. 5. ISBN 0-7817-1502-4.
  135. ↑ "-oma". Online Etymology Dictionary. Archived from the original on 2020-10-30. Retrieved 2020-03-25.
  136. ↑ "Search of: Lymphoma – List Results – ClinicalTrials.gov". Archived from the original on 2013-01-06. Retrieved 2012-10-30.
  137. ↑ "Understanding Clinical Trials for Blood Cancers" (PDF). The Leukemia & Lymphoma Society. Leukemia and Lymphoma Society. Archived from the original (PDF) on 5 January 2011. Retrieved 19 May 2010.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Lymphoma&oldid=1362628409"